Serdexmethylphenidate/dexmethylphenidate
 | |
 | |
| Combination of | |
|---|---|
| Serdexmethylphenidate | Catecholamine reuptake inhibitor |
| Dexmethylphenidate | Catecholamine reuptake inhibitor |
| Clinical data | |
| Trade names | Azstarys |
| Other names | KP415 |
| License data | |
| ATC code |
|
| Legal status | |
| Legal status |
|
Serdexmethylphenidate/dexmethylphenidate, sold under the brand name Azstarys, is a fixed-dose combination medication used to treat attention deficit hyperactivity disorder (ADHD) in people aged six years and older.[1]
It was approved for medical use in the United States in March 2021.[1]
References
- ^ a b "KemPharm Announces FDA Approval of Azstarys (serdexmethylphenidate and dexmethylphenidate capsules, for oral use, CII), A New Once-Daily Treatment for ADHD" (Press release). KemPharm. 3 March 2021. Retrieved 3 March 2021 – via GlobeNewswire.
External links
- "Serdexmethylphenidate". Drug Information Portal. U.S. National Library of Medicine.
- "Dexmethylphenidate". Drug Information Portal. U.S. National Library of Medicine.
 | This drug article relating to the nervous system is a stub. You can help Wikipedia by expanding it. |